bimagrumab and tirzepatide Update from #ADA2025 : 🧬 Bimagrumab Targets Activin Pathway in Obesity – Dual Action Molecule 👨‍⚕️ #ADA2025 #Obesity #WeightLoss 🔹 What is Bimagrumab? A monoclonal antibody that blocks activin type II The BELIEVE Trial: Rethinking What

Benefits Lose up to 15% of body weight Improve blood sugar control Lower blood pressure Boost energy levels Whos a Good Fit?

Wondering how semaglutide works for weight loss among non-diabetics

Esses avanos teraputicos marcam uma revoluo no manejo das doenas metablicas e da obesidade.Os tratamentos com agonistas dos receptores GLP-1 e GIP, embora eficazes no manejo da obesidade e dos distrbios metablicos, podem causar efeitos colaterais que frequentemente levam interrupo das terapias

You already know about the gastrointestinal ones.

As healthcare professionals, the onus lies on us to stay informed about the most effective weight management solutions, including cutting-edge treatments such as Semaglutide, Tirzepatide, and other GLP-1 receptor agonists.

Understand GLP-1 side effects, from short-term nausea to long-term risks